Orlando-based startup AireHealth announced an open-call for collaborators and innovators to help apply the firm’s technology to help coronavirus patients.

AireHealth Portable Connected Nebulizer

Orlando startup AireHealth, based in the University of Central Florida (UCF) Research Park Incubator, has a portable nebulizer that uses a proprietary delivery mechanism to significantly enhance the delivery of drugs for lung related treatments and therapies.

That’s why on March 30, AireHealth announced it was eager to help support the national effort to stem the impacts of the novel Coronavirus, putting out a call for collaborators to help apply the firm’s technology to help coronavirus patients.

Cofounder and CEO Stacie Ruth told the Orlando Business Journal, “We took what we absolutely have and we’re ready to move forward with, and we looked for the ways we could take those strengths and do something special with the COVID-19 response.”

The company’s portable and connected nebulizer has already cleared the FDA and Ruth and cofounder Jason Eichenholz are interested in partnering with innovators to have an impact, particularly for the patients with chronic respiratory conditions such as asthma and COPD that AireHealth already serves. 

“We’re enhancing our production and distribution strategies to include delivery of COVIDCare Kits that package a seven-day disposable supply for our nebulizer,” Ruth shared in a message on AireHealth’s website.

“We are also working on a retooled version of our AireHealth mobile app to track COVID-19 symptoms and communicate status to caregivers and physicians as required.”

Stacie Ruth, AireHealth Cofounder and CEO

AireHealth is seeking to partner with companies with cleared, exempt and fast-tracked respiratory device peripherals and sensors. Specifically, the company is seeking to collaborate with drug makers and pharmacies to enhance COVID-19 home care with known and novel respiratory drug delivery via its nebulizer. AireHealth will remotely monitor health status and deliver prescribed drug therapy for high risk respiratory patients at home by connecting partner solutions to the AireHealth COVIDCare App.  

The company is also seeking relationships with virtual care providers, device integrators, Telehealth platforms, distribution partners and response coordinators. Partners are required to fund and staff contributions to the effort and follow a rapid deployment model. 

“Bring your superstars, your doers to the table – we will bring ours,” Ruth shared. “Since the public appeal, several companies have stepped up and, as we join forces, we are making huge strides in the future of respiratory care in the home. We feel confident that we will have a collaborative solution launch this summer and we can feel the excitement building toward our future.”

Companies big and small interested in responding to AireHealth’s open call for innovators and collaborators should contact covidcare@aire.health.